A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Biomarkers Development


MOBILion and International Research Team are Awarded Grant from The Michael J. Fox Foundation

   by Lucy Shaw    107
MOBILion and International Research Team are Awarded Grant from The Michael J. Fox Foundation

MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease.

Arena International Announces the Brand New Direct-to-Patient and Virtual Clinical Trials Digital Experience

   by Kadin Luong    258
Arena International Announces the Brand New Direct-to-Patient and Virtual Clinical Trials Digital Experience

London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.

[Interview] Hacking Metabolomics With AI To Improve Clinical Research

   by Andrii Buvailo    1058
[Interview] Hacking Metabolomics With AI To Improve Clinical Research

Personalized medicine has become a paradigm-shifting trend in healthcare - the hegemony of  “one-size-fits-all” drugs is increasingly challenged by novel innovative modalities and therapies, laser-sharped for a specific group of patients, or even a single patient in some cases. This is a complex story, and the progress in personalized medicine will take time and tectonic shifts in the pharmaceutical research workflow. 

On the other hand, the advent of personalized medicine is only possible with a more personalized system for health assessment, new robust biomarkers, and novel approaches to run and monitor clinical trials. This will require diagnostics that can provide sufficient insight into the metabolic status of individuals, and relatively new science of metabolomics is now taking off in the biotech industry.